Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression

NCT01627782 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT01627782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01627782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 2
Overall status
Completed
Start date
August 6, 2012
Completion date
September 12, 2013
Enrollment
68 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder